Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biosearch Technologies Launches New, ISO Certified GMP Production Facility

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Biosearch Technologies, Inc. (Biosearch) announced the relocation of its GMP manufacturing process into a new, state-of-the-art GMP production facility in Novato, California.

The 30,000 square foot facility was developed to further expand processes and controls relevant to medical device and molecular diagnostic customers.

“The GMP production facility is designed to incorporate the environmental and access controls, linear production flow and clean room processes critical for the controlled manufacture of highly-qualified diagnostic components, reagents and kits,” said Ron Cook, President and CEO of Biosearch Technologies.  “Our new facility allows us to continue to support our diagnostic customers in a manner fully compliant with customer and regulatory requirements.  This advanced facility also introduces pharmaceutical scale lyophilization capabilities allowing for state-of-the-art processing of molecular diagnostic assays in large scale single batches and all format types.”

In addition to the relocation to the new GMP production facility, Biosearch has successfully completed certification to ISO 13485:2003.  This certification confirms that Biosearch has developed, implemented and maintains a Quality Management System able to meet the stringent requirements of medical device and molecular diagnostic manufacturing.

“Certification to ISO 13485 is a significant milestone for Biosearch and its GMP and Commercial Services production group,” said Jason Erickson, Director of Quality at Biosearch Technologies.  “We have taken great strides to ensure a robust Quality Management System and successful certification to this standard demonstrates our commitment to quality at all levels within our organization.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biosearch Acquires Worldwide Rights to Non-FRET Probes Patents
Company has acquired rights from UMDNJ to United States Patent 6,150,097.
Thursday, August 23, 2012
Biosearch Appoints Uniscience as Brazilian Distributor
Uniscience to sell, market, and support Biosearch’s inventoried and custom products in the country of Brazil.
Tuesday, May 22, 2012
Biosearch and IMDx Finalize cGMP Oligo Supply and Licensing Agreements for IVD Products
Biosearch will manufacture cGMP oligonucleotides for IMDx for use in human in-vitro diagnostics.
Wednesday, March 16, 2011
Biosearch Technologies Licenses Access to new CDC “PDM” H1N1 Signatures
New “pdm” panel is optimized to achieve enhanced sensitivity and specificity for H1N1 specimen.
Friday, November 19, 2010
Biosearch Technologies Awarded Second Phase II Army SBIR Grant
The $750,000+ Phase II grant will continue the design and development of accurate assays for pathogens of military importance.
Thursday, October 14, 2010
Biosearch Technologies Awarded Phase II Army SBIR Grant
The $800,000+ Phase II grant is aimed to back the design and development of rapid and accurate assays for pathogens of military importance.
Thursday, September 23, 2010
Biosearch Technologies Expands Licensing of QIAGEN Scorpions®
According to the agreement, the company obtains rights to manufacture primer assays for research, applied markets and infectious diseases.
Friday, August 13, 2010
Biosearch Expands Licensing of Roche Patents to Manufacture Kits Targeting the in-vitro Diagnostic Industry
License allows Biosearch to develop kits comprising of probes, primers, enzymes to amplify and detect diagnostic targets.
Wednesday, March 10, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!